Business Context and Reporting Period
This Form 8-K is a current report filed by Stellar Biotechnologies, Inc. (not Edesa Biotech, Inc.) on May 23, 2018, covering events occurring on May 21 and May 22, 2018. The registrant is incorporated in British Columbia, Canada, and maintains its principal executive offices in Port Hueneme, California.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on regulatory compliance and share count updates.
Material Changes
- Nasdaq Compliance: The Company regained compliance with Nasdaq Listing Rule 5550(a)(2) regarding the minimum bid price requirement. The closing bid price for common shares remained at $1.00 or greater for ten consecutive business days, closing the prior deficiency matter.
- Share Count Update: As of May 22, 2018, the Company had 3,292,304 common shares issued and outstanding. This total includes 401,038 shares issued from the exercise of pre-funded warrants related to a best efforts public offering disclosed on May 15, 2018.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or discussion of new risks and contingencies. The document serves solely to notify the market of the resolution of the Nasdaq listing deficiency and the updated capitalization structure.
Investor Verification Checklist
- Verify the current trading price of Stellar Biotechnologies, Inc. common shares to confirm sustained compliance with Nasdaq listing rules.
- Confirm the total number of outstanding shares (3,292,304) and the impact of the 401,038 shares issued via pre-funded warrant exercises on dilution.
- Review the May 15, 2018 Form 8-K for details regarding the best efforts public offering of units and pre-funded units.